mc2-25

Small moleculeexperimental

Clinical trial activity

4 trials · 2 clinical orgs · 0 marketing orgs

Phase 1
1
Phase 2
3
Phase 3
0
Phase 4
0

Earliest trial started Feb 1, 2022 (NCT05853471)

Timeline

2020s

  1. Jan 1, 2022

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2022

    Earliest Phase 2 Sponsor(trial)

Indications

Mechanism of action

  • Unspecified target

    isocyanate scavenger

Chemistry & pharmacology

Oral

No

Parenteral

No

Topical

No

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT06132919Phase 2Oct 11, 2023MC2 Therapeutics
NCT05618119N/AJan 1, 2023University of Groningen
NCT05482698Phase 2Jul 1, 2022MC2 Therapeutics
NCT05853471Phase 1/Phase 2 (Phase 2)Feb 1, 2022University of Groningen
Showing 4 of 4 trials
Page 1 / 1

Organizations

Research & Development (2)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
MC2 TherapeuticsFor profit2212022
University of GroningenAcademic/Hospital2222022
2 organizations
Page 1 / 1